

Antibody Engineering & Therapeutics

December 11-15, 2017
Manchester Grand Hyatt
San Diego, CA

Annual Meeting
of the
**ANTI
BODY
SOCI
ETY**

THE LARGEST MEETING BRINGING YOU THE LATEST ANTIBODY SCIENCE, TECHNOLOGIES AND PARTNERS NEEDED TO ACCELERATE NEXT GENERATION ANTIBODIES TOWARDS COMMERCIAL SUCCESS

The Most Innovative Science Presented by Leading Industry and Academic Experts

The Largest Exhibition Devoted to Antibody Engineering

The Leading Forum to Partner with Global Antibody Innovators and Suppliers

Keynotes Speakers Share Strategies to Accelerate Your Antibody Molecules

DECIPHERING THE HUMAN IMMUNOME

James E. Crowe, Jr., M.D.,
Director, Vanderbilt Vaccine Center, Vanderbilt
University Medical Center




PARACRINE DELIVERY

Andreas Plückthun, Ph.D.,
Professor and Director,
Department of Biochemistry,
University of Zürich, Switzerland



BIOLOGIC DRUG DELIVERY ACROSS THE BLOOD-BRAIN BARRIER WITH IgG FUSION PROTEINS

William M. Pardridge, M.D.,
Distinguished Professor Emeritus, UCLA and
Founder and Chief Scientific Officer, ArmaGen



Register by June 30 and Save Up to \$600

ENGINEERING AND APPLICATION OF THERAPEUTIC ANTIBODIES FOR NEURODEGENERATIVE DISEASES

Session Co-Chairs:

Cynthia A. Lemere, Ph.D., Associate Professor of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School

Anne Messer, Ph.D., Professor of Biomedical Sciences, University at Albany and Principal Investigator, Neural Stem Cell Institute, Regenerative Research Foundation

James S. Huston, Ph.D., Chairman, The Antibody Society; Managing Member, Huston BioConsulting, LLC

Towards Development of Antibody Therapy for C9orf72 ALS/FTD

Laura P.W. Ranum, Ph.D., Director, Center for NeuroGenetics, Kitzman Family Professor of Molecular Genetics and Microbiology, College of Medicine, University of Florida

Antibody Therapy for Alzheimer's Disease – Key Challenges

Christoph Hock, M.D., Professor and Director, Institute for Regenerative Medicine (IREM), University of Zurich and Co-Founder, Neurimmune, Switzerland

Altering APP Processing with a Proteolytic Diabody

Michael Sierks, Ph.D., Professor, Chemical Engineering, Arizona State University

Tau Immunotherapy

Peter Davies, Feinstein Institute for Medical Research, North Shore/LIJ Health System

PD Immunotherapy – A-Syn

Eliezer Masliah, M.D., Director, Division of Neurosciences, National Institutes of Aging, NIH

BIOLOGICAL IMPACT OF FC RECEPTOR ENGAGEMENT

Session Co-Chairs:

Trudi Veldman Ph.D., Senior Director Biologics, AbbVie Bioresearch Center
Chung-Ming Hsieh, Executive Director, Biologics Discovery Boston, Merck Research Laboratories

SKY59: Novel Recycling Antibody against C5 with Improved Pharmacokinetics for the Treatment of Complement-mediated Diseases

Kenta Haraya, Ph.D., Scientist, Research Division, Biologics Discovery, Chugai Pharmaceutical Co Ltd., Japan

Novel Effector Function Attenuating Mutations That Maintain Antibody Stability and Reduce Toxicity

James A. Ernst, Ph.D., Senior Scientist & Group Leader, Department of Protein Sciences, Genentech

Selective Fc γ R Engagement by Agonistic Anti-CD40 Abs

Rony Dahan, Ph.D., Principal Investigator, Department of Immunology, Weizmann Institute of Science, Israel

Antibody Optimization for Treg Depletion in Cancer Therapy

Frederick Arce Vargas, M.D. Ph.D., Research Associate, University College London Cancer Institute, United Kingdom

Potent Antitumor Activity of IL2-Fc Requires Fc-mediated Depletion of Tregs

Daniel Christ, Ph.D., Associate Professor and Head Antibody Therapeutics, Director Centre for Targeted Therapy, Immunology Program, Garvan Institute of Medical Research

IMMUNO-ONCOLOGY: CHECKPOINTS

Session Chair:

James Larrick, M.D., Ph.D., Managing Director and Chief Medical Officer, Panorama Research Institute and Velocity Pharmaceutical Development

Development of GARP

Hans de Haard, Ph.D., Chief Scientific Officer, Argenx, Belgium

Megakine: A Novel Receptor Agonist Bispecific Antibody

Cheng-I Wang, Ph.D. Principle Investigator Technologist, Antibodies, Singapore Immunology Network, A*Star, Singapore

ROLE OF POST-TRANSLATIONAL MODIFICATION IN ANTIBODY FUNCTION

Session Co-Chairs:

Dennis R. Burton, Ph.D., Professor, Department of Immunology and Microbial Science, The Scripps Research Institute

Paul Parren, Ph.D., Senior Vice President and Scientific Director, Genmab, The Netherlands

Integrative Mass Spectrometric Structural Analysis of Glycoprotein Therapeutics and Its Usage to Evaluate and Score Biosimilarity

Albert J. R. Heck, Ph.D., Professor and Science Faculty, Utrecht University, The Netherlands

Post-translational Modification of Antibodies in Rheumatoid Arthritis

Leendert A. Trouw Ph.D., Assistant, Department of Immunohematology and Bloodtransfusion, Leiden University Medical Center, Leiden, The Netherlands

Regulation of Autoantibody Activity by the IL-23–TH17 Axis and Its Impact on Autoimmune Disease

Gerhard Krönke, M.D., Professor of Translational Immunology, Department of Internal Medicine 3, Institute of Rheumatology and Immunology, University of Erlangen-Nuremberg Germany

Fc Fucosylation and Sialylation and Antibody Effector Function

Jeffrey Ravetch, Ph.D., Professor, Rockefeller University

Sulfation of Broadly Neutralizing HIV Antibodies

Raiees Andrabi, Research Associate, The Burton Lab, The Scripps Research Institute

ANTIBODY BASED INNOVATIONS IN THE TUMOR MICROENVIRONMENT

Session Co-Chairs:

Kerry A. Chester, Ph.D., Professor of Molecular Medicine, UCL Cancer Institute, University College London, *United Kingdom*

Janine Schuurman, Ph.D., Vice President, Research, Genmab, *The Netherlands*

Protia – Bispecific T-Cell Engagers Designed for Local Activation in the Tumor Environment

Volker Schellenberger, Ph.D., CEO and President, Amunix

Immuno-Viral Therapy for Solid Tumors

Maria Navarro, M.D., Project & Operations Manager, Icell Kealex Therapeutics

Costimulation of Immune Cells in the Tumor Microenvironment via Bispecific DART® and TRIDENT™ Molecules

Syd Johnson, Ph.D., Vice President, Antibody Engineering, MacroGenics

Harnessing Fc Gamma Receptor Biology to Optimize Antibodies Targeting TNFR Superfamily Members

Nick Wilson, Ph.D., Executive Director of Immuno-modulatory Drug Discovery, Agenus

mRNA Vaccination and Combination Therapy with Immunomodulating Antibodies

Sebastian Kreiter, Head, Tron/BioNTech, *Germany*

An Update on the Darzalex Story

Kate Sasser, Ph.D., Vice President, Head of Oncology Translational Research, Janssen

OVERCOMING DELIVERY CHALLENGES INCLUDING BRAIN AND INTRACELLULAR TARGETS

Session Co-Chairs:

Paul J. Carter, Ph.D., Senior Director and Staff Scientist, Antibody Engineering, Genentech, Inc.

Andreas Plückthun, Ph.D., Professor and Director, Department of Biochemistry, University of Zürich, *Switzerland*

Bacterial Secretion Systems

Thomas Marlovits, Professor, Institute of Molecular Pathology, *Austria*

Nanobodies as Inhaled Biotherapeutics for Lung Diseases, with ALX-0171 (anti-RSV) as a Case Study

Antonin De Fourgerolles, Ph.D., Chief Scientific Officer, Ablynx, *Belgium*

Bispecific Antibodies Targeting Transferin Receptor or CD98 to Facilitate Delivery across the Blood Brain Barrier

Jasi Atwal, Scientist, Genentech

Artificial immunotoxins

Ernst Wagner, Ph.D., Chair, Pharmaceutical Biotechnology, Center for System-based Drug Research, Center for Nanoscience, Ludwig Maximilians University, *Germany*

ANTIBODY-DRUG CONJUGATES & FUSION PROTEINS

Session Chair:

Gregory Adams, Ph.D., Chief Scientific Officer, Eleven Biotherapeutics

Redox Selenium ADCs Improve Cancer Cell Monoclonal Antibody Cytotoxicity

Julian Spallholz, Ph.D., Professor, Nutritional Sciences, Texas Tech University

Antibody-drug Conjugates for Treating Steroid-resistant Malignancies and Autoimmune Diseases

Masahiro Yasunaga, M.D., Ph.D., Unit Leader, Developmental Therapeutics, National Cancer Center, *Japan*

Targeting Tumors and Their Vasculature with Antibody-drug Conjugates

Dimitar Dimitrov, Ph.D., Senior Investigator, CCR, Cancer and Inflammation Program, NCI-Frederick, NIH

Novel Calicheamicin Antibody-Drug Conjugates

Julia Gavrilyuk, Ph.D., Principal Scientist, Discovery Chemistry, Abbvie Stemcentrx

NOVEL ANTIBODY DISPLAY, SELECTION AND SCREENING TECHNOLOGIES

Session Chair:

Andrew Bradbury, M.D., Ph.D., Research Scientist and Group Leader, Los Alamos National Laboratories

VACCINES AND IMMUNOTHERAPY

Session Chair:

Mark Alfenito, Ph.D., President and CEO, EnGen Bio, LLC

ROLE OF THE T-CELL REPERTOIRE IN CANCER, INFECTIOUS DISEASES AND AUTOIMMUNITY

Session Chair:

Jamie K. Scott, M.D., Ph.D., Professor and Canada Research Chair in Molecular Immunity, Department of Molecular Biology & Biochemistry and Faculty of Health Sciences, Simon Fraser University, Canada

OVERCOMING TUMOR-BASED RESISTANCE MECHANISMS TO ANTIBODY-INITIATED IMMUNE ATTACK

Session Chair:

Louis M. Weiner, M.D., Director, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center

ANTI-TUMOR ANTIGEN ANTIBODIES IN CANCER IMMUNOTHERAPY

Session Chair:

K. Dane Wittrup, Ph.D., C.P. Dubbs Professor of Chemical Engineering and Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology